Developer docs
API playgroundTry for free, no card

Search company profiles

Cour Pharmaceuticals Development

Full company profile

uuid0000fey

Namestring
Cour Pharmaceuticals Development
Legal namestring
COUR Pharmaceuticals
Websiteurl
courpharma.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

COUR Pharmaceuticals Development is a clinical-stage biotechnology company headquartered in Skokie, Illinois that develops antigen-specific immune tolerance therapies using a proprietary immune-modifying nanoparticle platform. The technology encapsulates disease-relevant autoantigens into nanoparticles that are delivered to the liver to leverage the body's endogenous pathway for reinforcing self-tolerance, thereby reprogramming pathogenic T and B cell responses while preserving normal immune function. The company's stated thesis is to address the underlying autoimmune cause of disease rather than suppress symptoms with broad immunosuppression.

The pipeline comprises four product candidates spanning multiple autoimmune indications. CNP-104 targets Primary Biliary Cholangitis (PBC) and has both Orphan Drug and Fast Track FDA designations, with positive one-year Phase 2a data reported in March 2026. CNP-103 targets Type 1 Diabetes, received Fast Track Designation in March 2025, and entered first-in-human Phase 1 testing in August 2025. CNP-106 targets Myasthenia Gravis and is in a Phase 1b/2a trial across approximately 30 centers in the United States and Canada, with Orphan Drug Designation. CNP-101/TAK-101 targets Celiac Disease and is partnered with Takeda, which is conducting a Phase 2b study after licensing the asset in 2019; this was the first clinical trial to demonstrate induction of antigen-specific immune tolerance in humans.

The company is pre-revenue with a documented business model centered on future pharmaceutical product sales supplemented by licensing and royalty arrangements, evidenced by the Takeda partnership structure for CNP-101. To date COUR has raised over $185 million across multiple rounds led by Alpha Wave Ventures, Lumira Ventures, and Roche Venture Fund, with corporate venture participation from Roche, Sanofi, Pfizer Ventures, and Bristol-Myers Squibb. Headcount is reported at 51–100 employees, and the company reaches patient populations through its corporate website, dedicated trial recruitment sites, and partnerships with patient advocacy organizations including Breakthrough T1D, the American Liver Foundation, the Myasthenia Gravis Foundation of America, and the Celiac Disease Foundation.

Short descriptiontext

COUR Pharmaceuticals Development is a clinical-stage biotechnology company developing proprietary antigen-specific immune tolerance nanoparticle therapies that target the root cause of autoimmune diseases, with four pipeline candidates in PBC, Type 1 Diabetes, Myasthenia Gravis, and Celiac Disease.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSkokie, United States
HQ citystring
Skokie
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immune tolerance therapy, autoimmune disease therapeutics, nanoparticle drug delivery, clinical stage biotechnology, antigen-specific immunotherapy
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Autoimmune Disease Biopharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotechnology company. Revenue will be generated through sales of FDA-approved therapies once clinical development is completed. The company is also pursuing partnership models (e.g., Takeda partnership for CNP-101) for co-development and commercialization.

courpharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

COUR Pharma is a clinical-stage biotechnology company developing proprietary antigen-specific immune tolerance therapies encapsulated in nanoparticles. Its pipeline includes CNP-104 for Primary Biliary Cholangitis, CNP-103 for Type 1 Diabetes, CNP-106 for Myasthenia Gravis, and CNP-101/TAK-101 (partnered with Takeda) for Celiac Disease. The platform reprograms the immune system to halt autoimmune destruction while preserving normal immune function.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Improved liver stiffness measurements and achievement of composite biochemical response criteria in Phase 2a PBC study
+2 more records
Product overview1 text field

COUR Pharma is a clinical-stage biotechnology company developing targeted immune tolerance therapies through its proprietary nanoparticle platform technology. The company's portfolio consists of four main product candidates: CNP-104 (Phase 2 for Primary Biliary Cholangitis), CNP-103 (Phase 1/2 for Type 1 Diabetes), CNP-106 (Phase 1b/2a for Myasthenia Gravis), and CNP-101/TAK-101 (Phase 2b for Celiac Disease, partnered with Takeda). All products use antigen-specific immune tolerance approaches to address the root cause of autoimmune diseases rather than simply managing symptoms.

Product and service4 records
1CNP-104
CategoryCore product - clinical-stage therapeutic candidate
Description

Antigen-specific immune tolerance therapy for Primary Biliary Cholangitis that encapsulates the autoantigen PDC-E2 to reprogram the immune system and halt bile duct destruction. Granted FDA Orphan Drug Designation (December 2024) and Fast Track Designation (January 2022).

2CNP-103
CategoryCore product - clinical-stage therapeutic candidate
Description

Investigational antigen-specific immune tolerance therapy for Type 1 Diabetes that encapsulates four recombinant proteins covering more than 95% of antigens driving T1D to retrain the immune system and prevent beta-cell destruction. Granted FDA Fast Track Designation in March 2025.

3CNP-106
CategoryCore product - clinical-stage therapeutic candidate
Description

Disease-modifying antigen-specific immune tolerance therapy for Myasthenia Gravis that encapsulates AChR-associated autoantigens to reprogram the immune system and regulate AChR antibody-producing B cells. Granted FDA Orphan Drug Designation.

4CNP-101/TAK-101
CategoryPartnered product - licensed to Takeda
Description

First-in-class antigen-specific immune tolerance therapy for Celiac Disease designed to reprogram the immune system to recognize gluten as harmless. Licensed to Takeda in 2019 and currently in Phase 2b study. First clinical trial to demonstrate induction of antigen-specific immune tolerance in humans.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Takeda acquired the license for CNP-101 (TAK-101) in 2019 for celiac disease development. Takeda is enrolling patients in a Phase 2b study. Takeda is also mentioned as a partner for autoimmune disease in the pipeline section.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases using a proprietary platform. Most directly comparable peer as both companies share the antigen-specific tolerance approach for celiac and other autoimmune indications.

TypeDirect peer
Description

Developer of nanoparticle-based immune tolerance therapies (Navacim platform) that reprogram immune cells to treat autoimmune disease. Closely comparable technology modality to COUR's PLG-based nanoparticles.

TypeDirect peer
Description

Clinical-stage company developing nanoparticle-based tolerance induction therapies for autoimmune diseases, including celiac and multiple sclerosis. Closely comparable in platform modality and target indications.

4Selecta Biosciences
TypeDirect peer
Description

Pioneer in tolerogenic nanoparticle immunotherapies (ImmTOR platform) designed to induce antigen-specific immune tolerance. Closely aligned in modality though historically focused on enzyme replacement and gene therapy contexts.

TypeBroad incumbent
Description

Global pharmaceutical company that licensed COUR's CNP-101 (TAK-101) for celiac disease in 2019 and is currently running a Phase 2b study. Functions as both a strategic partner and a broader autoimmune competitor with deep GI pipeline resources.

TypeBroad incumbent
Description

Leading competitor in Type 1 Diabetes with VX-880/zimislecel islet cell therapy program in clinical development. Represents the most credible alternative modality to COUR's CNP-103 in the T1D indication.

TypeDirect peer
Description

Acquired by Sanofi in 2023, Provention developed teplizumab (Tzield) — the first FDA-approved disease-modifying therapy for T1D. Directly comparable as a T1D immunotherapy competitor with regulatory approval.

TypeBroad incumbent
Description

Swiss pharmaceutical major that is both a COUR investor (via Roche Venture Fund co-leading the Series B) and a broad autoimmune competitor with extensive biologics portfolios across neurology, gastroenterology, and immunology.

TypeBroad incumbent
Description

Global pharma investor in COUR's Series B via Pfizer Ventures. Operates broadly in autoimmune and rare disease, with portfolio companies and internal programs competing for autoimmune indications COUR targets.

TypeBroad incumbent
Description

Global pharma and new Series B investor in COUR. Operates a broad immunology and rare disease portfolio, including the recently acquired Provention Bio teplizumab for T1D — making it both a strategic capital provider and a T1D competitive force.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cour Pharmaceuticals Development

Autoimmune Disease Biopharmaceuticalscourpharma.com

COUR Pharmaceuticals Development is a clinical-stage biotechnology company developing proprietary antigen-specific immune tolerance nanoparticle therapies that target the root cause of autoimmune diseases, with four pipeline candidates in PBC, Type 1 Diabetes, Myasthenia Gravis, and Celiac Disease.

What Cour Pharmaceuticals Development does

COUR Pharmaceuticals Development is a clinical-stage biotechnology company headquartered in Skokie, Illinois that develops antigen-specific immune tolerance therapies using a proprietary immune-modifying nanoparticle platform. The technology encapsulates disease-relevant autoantigens into nanoparticles that are delivered to the liver to leverage the body's endogenous pathway for reinforcing self-tolerance, thereby reprogramming pathogenic T and B cell responses while preserving normal immune function. The company's stated thesis is to address the underlying autoimmune cause of disease rather than suppress symptoms with broad immunosuppression.

The pipeline comprises four product candidates spanning multiple autoimmune indications. CNP-104 targets Primary Biliary Cholangitis (PBC) and has both Orphan Drug and Fast Track FDA designations, with positive one-year Phase 2a data reported in March 2026. CNP-103 targets Type 1 Diabetes, received Fast Track Designation in March 2025, and entered first-in-human Phase 1 testing in August 2025. CNP-106 targets Myasthenia Gravis and is in a Phase 1b/2a trial across approximately 30 centers in the United States and Canada, with Orphan Drug Designation. CNP-101/TAK-101 targets Celiac Disease and is partnered with Takeda, which is conducting a Phase 2b study after licensing the asset in 2019; this was the first clinical trial to demonstrate induction of antigen-specific immune tolerance in humans.

The company is pre-revenue with a documented business model centered on future pharmaceutical product sales supplemented by licensing and royalty arrangements, evidenced by the Takeda partnership structure for CNP-101. To date COUR has raised over $185 million across multiple rounds led by Alpha Wave Ventures, Lumira Ventures, and Roche Venture Fund, with corporate venture participation from Roche, Sanofi, Pfizer Ventures, and Bristol-Myers Squibb. Headcount is reported at 51–100 employees, and the company reaches patient populations through its corporate website, dedicated trial recruitment sites, and partnerships with patient advocacy organizations including Breakthrough T1D, the American Liver Foundation, the Myasthenia Gravis Foundation of America, and the Celiac Disease Foundation.

Cour Pharmaceuticals Development firmographics

Firmographics
Name
Cour Pharmaceuticals Development
Legal name
COUR Pharmaceuticals
Website
https://courpharma.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
COUR Pharmaceuticals Development is a clinical-stage biotechnology company developing proprietary antigen-specific immune tolerance nanoparticle therapies that target the root cause of autoimmune diseases, with four pipeline candidates in PBC, Type 1 Diabetes, Myasthenia Gravis, and Celiac Disease.
Ownership category
akta.pro rank

Cour Pharmaceuticals Development industry classification

Industry
Product category
Autoimmune Disease Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Immune tolerance therapy
  • Autoimmune disease therapeutics
  • Nanoparticle drug delivery
  • Clinical stage biotechnology
  • Antigen-specific immunotherapy

Where Cour Pharmaceuticals Development is headquartered

Location

Headquarters

HQ city
Skokie
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cour Pharmaceuticals Development business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical product sales: Pre-revenue clinical-stage biotechnology company. Revenue will be generated through sales of FDA-approved therapies once clinical development is completed. The company is also pursuing partnership models (e.g., Takeda partnership for CNP-101) for co-development and commercialization.

Go-to-market motion1 record

Marketing channels3 records

Cour Pharmaceuticals Development product offering

Product offering

Core offering

COUR Pharma is a clinical-stage biotechnology company developing proprietary antigen-specific immune tolerance therapies encapsulated in nanoparticles. Its pipeline includes CNP-104 for Primary Biliary Cholangitis, CNP-103 for Type 1 Diabetes, CNP-106 for Myasthenia Gravis, and CNP-101/TAK-101 (partnered with Takeda) for Celiac Disease. The platform reprograms the immune system to halt autoimmune destruction while preserving normal immune function.

Product overview

COUR Pharma is a clinical-stage biotechnology company developing targeted immune tolerance therapies through its proprietary nanoparticle platform technology. The company's portfolio consists of four main product candidates: CNP-104 (Phase 2 for Primary Biliary Cholangitis), CNP-103 (Phase 1/2 for Type 1 Diabetes), CNP-106 (Phase 1b/2a for Myasthenia Gravis), and CNP-101/TAK-101 (Phase 2b for Celiac Disease, partnered with Takeda). All products use antigen-specific immune tolerance approaches to address the root cause of autoimmune diseases rather than simply managing symptoms.

Differentiator

Problem solved

Functional benefit

Products and services

  • CNP-104 Antigen-specific immune tolerance therapy for Primary Biliary Cholangitis that encapsulates the autoantigen PDC-E2 to reprogram the immune system and halt bile duct destruction. Granted FDA Orphan Drug Designation (December 2024) and Fast Track Designation (January 2022).
  • CNP-103 Investigational antigen-specific immune tolerance therapy for Type 1 Diabetes that encapsulates four recombinant proteins covering more than 95% of antigens driving T1D to retrain the immune system and prevent beta-cell destruction. Granted FDA Fast Track Designation in March 2025.
  • CNP-106 Disease-modifying antigen-specific immune tolerance therapy for Myasthenia Gravis that encapsulates AChR-associated autoantigens to reprogram the immune system and regulate AChR antibody-producing B cells. Granted FDA Orphan Drug Designation.
  • CNP-101/TAK-101 First-in-class antigen-specific immune tolerance therapy for Celiac Disease designed to reprogram the immune system to recognize gluten as harmless. Licensed to Takeda in 2019 and currently in Phase 2b study. First clinical trial to demonstrate induction of antigen-specific immune tolerance in humans.

Quantifiable outcome

  • Improved liver stiffness measurements and achievement of composite biochemical response criteria in Phase 2a PBC study
  • +2 more outcomes

Companies that use Cour Pharmaceuticals Development

Customer profile

Segments4 records

Ideal customer profiles2 records

Cour Pharmaceuticals Development technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cour Pharmaceuticals Development partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • TakedacoreStrategic or Co-development Partner · 1 January 2019Takeda acquired the license for CNP-101 (TAK-101) in 2019 for celiac disease development. Takeda is enrolling patients in a Phase 2b study. Takeda is also mentioned as a partner for autoimmune disease in the pipeline section.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Cour Pharmaceuticals Development competitors and assessment

Company assessment

Direct peers

  • Anokion: Clinical-stage biotech developing antigen-specific immune tolerance therapies for autoimmune diseases using a proprietary platform. Most directly comparable peer as both companies share the antigen-specific tolerance approach for celiac and other autoimmune indications.
  • Parvus Therapeutics: Developer of nanoparticle-based immune tolerance therapies (Navacim platform) that reprogram immune cells to treat autoimmune disease. Closely comparable technology modality to COUR's PLG-based nanoparticles.
  • Topas Therapeutics: Clinical-stage company developing nanoparticle-based tolerance induction therapies for autoimmune diseases, including celiac and multiple sclerosis. Closely comparable in platform modality and target indications.
  • Selecta Biosciences: Pioneer in tolerogenic nanoparticle immunotherapies (ImmTOR platform) designed to induce antigen-specific immune tolerance. Closely aligned in modality though historically focused on enzyme replacement and gene therapy contexts.
  • Provention Bio (a Sanofi company): Acquired by Sanofi in 2023, Provention developed teplizumab (Tzield) — the first FDA-approved disease-modifying therapy for T1D. Directly comparable as a T1D immunotherapy competitor with regulatory approval.

Broad incumbents

  • Takeda Pharmaceutical: Global pharmaceutical company that licensed COUR's CNP-101 (TAK-101) for celiac disease in 2019 and is currently running a Phase 2b study. Functions as both a strategic partner and a broader autoimmune competitor with deep GI pipeline resources.
  • Vertex Pharmaceuticals: Leading competitor in Type 1 Diabetes with VX-880/zimislecel islet cell therapy program in clinical development. Represents the most credible alternative modality to COUR's CNP-103 in the T1D indication.
  • Roche: Swiss pharmaceutical major that is both a COUR investor (via Roche Venture Fund co-leading the Series B) and a broad autoimmune competitor with extensive biologics portfolios across neurology, gastroenterology, and immunology.
  • Pfizer: Global pharma investor in COUR's Series B via Pfizer Ventures. Operates broadly in autoimmune and rare disease, with portfolio companies and internal programs competing for autoimmune indications COUR targets.
  • Sanofi: Global pharma and new Series B investor in COUR. Operates a broad immunology and rare disease portfolio, including the recently acquired Provention Bio teplizumab for T1D — making it both a strategic capital provider and a T1D competitive force.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cour Pharmaceuticals Development social profiles

Digital presence

Cour Pharmaceuticals Development financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cour Pharmaceuticals Development leadership team

Management profile

Number of profiles

Profiles8 records

Cour Pharmaceuticals Development funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cour Pharmaceuticals Development M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cour Pharmaceuticals Development

What does Cour Pharmaceuticals Development do?

COUR Pharma is a clinical-stage biotechnology company developing proprietary antigen-specific immune tolerance therapies encapsulated in nanoparticles. Its pipeline includes CNP-104 for Primary Biliary Cholangitis, CNP-103 for Type 1 Diabetes, CNP-106 for Myasthenia Gravis, and CNP-101/TAK-101 (partnered with Takeda) for Celiac Disease. The platform reprograms the immune system to halt autoimmune destruction while preserving normal immune function.

Is Cour Pharmaceuticals Development a public or private company?

Cour Pharmaceuticals Development is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cour Pharmaceuticals Development founded?

Cour Pharmaceuticals Development was founded in 2015. It employs 51 to 100 people.

Where is Cour Pharmaceuticals Development based?

Cour Pharmaceuticals Development is headquartered in Skokie, United States, in the North America region.

How does Cour Pharmaceuticals Development make money?

One revenue line is on record: pharmaceutical product sales.

Who are Cour Pharmaceuticals Development's main competitors?

Direct peers on record are Anokion, Parvus Therapeutics, Topas Therapeutics, Selecta Biosciences and Provention Bio (a Sanofi company). Broad incumbents are Takeda Pharmaceutical, Vertex Pharmaceuticals, Roche, Pfizer and Sanofi.

Does Cour Pharmaceuticals Development have an API?

No public API is recorded for Cour Pharmaceuticals Development.

What industry is Cour Pharmaceuticals Development in?

Cour Pharmaceuticals Development's product category is Autoimmune Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pharmacy TimesFDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary CholangitisThe FDA granted orphan drug designation to CNP-104, developed by COUR Pharmaceuticals, for the treatment of primary biliary cholangitis. This decision follows positive top-line data from a phase 2a clinical trial which demonstrated that the treatment slowed disease progression and induced tolerance to pathogenic T-cells. The designation highlights the potential for CNP-104 to become the first disease-modifying treatment for this condition.PR NewswireHalozyme Appoints Dannielle Appelhans to its Board of DirectorsHalozyme Therapeutics announced the election of Dannielle Appelhans to its Board of Directors, citing her extensive executive leadership experience in biotechnology operations and supply chain management. This appointment is intended to support Halozyme's growth strategy as it scales its ENHANZE platform and advances new technologies like Hypercon and Surf Bio. Appelhans brings a track record of successful partnerships, including a major collaboration with Genentech during her tenure at COUR Pharmaceuticals.Stock TitanHalozyme Appoints Appelhans, 20+ Year Executive, to BoardHalozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors, citing her extensive executive leadership experience in biotechnology and pharmaceutical operations. Appelhans currently serves as CEO of COUR Pharmaceuticals and brings a track record of executing major partnerships, such as the strategic collaboration with Genentech. Her appointment is intended to support Halozyme's growth strategy for platforms like ENHANZE, Hypercon, and Surf Bio.BioSpaceCOUR Pharma Announces Closing of $50 Million Series BCOUR Pharma closed a $50 million Series B round led by Lumira Ventures and Roche Venture Fund, with Sanofi joining. The funds will advance CNP-103, an antigen-specific immune tolerance therapy for type 1 diabetes, in a Phase 2 trial. The company is also seeking partners for CNP-104 and CNP-106 in other autoimmune diseases.GlobeNewswireCOUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary CholangitisCOUR Pharma announced positive one-year results from its Phase 2a study of CNP-104 for Primary Biliary Cholangitis, demonstrating durable improvements in liver stiffness and composite biochemical response markers. The data showed sustained separation from placebo with a favorable safety profile, supporting the drug's potential as a novel therapeutic option. These findings will inform the company's ongoing development strategy and potential collaborations.MyastheniagravisnewsNew gMG therapy candidate boosts immune tolerance processesCour Pharmaceuticals published peer-reviewed data in Science Advances demonstrating that its experimental therapy CNP-106 restores immune tolerance in generalized myasthenia gravis by boosting regulatory T-cells. The study confirms that Cour's nanoparticle platform activates the STING/type I interferon pathway, providing a mechanistic basis for the company's ongoing Phase 1b/2a clinical trial.GlobeNewswireCOUR Pharma Publishes Peer-Reviewed Data in Science AdvancesCOUR Pharma published peer-reviewed data in Science Advances showing that its nanoparticle platform induces antigen-specific immune tolerance via the STING/type I interferon pathway. The study found that genetic disruption of this pathway abrogated tolerance induction, establishing it as mechanistically required. The findings support continued development of the platform across autoimmune diseases.GlobeNewswireCOUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia GravisCOUR Pharma received FDA orphan drug designation for CNP-106, an investigational therapy for generalized myasthenia gravis. The biodegradable nanoparticle encapsulates seven acetylcholine receptor antigens and is being evaluated in a Phase 1b/2a clinical trial. The company expects to share data readouts as enrollment continues.GlobeNewswireCOUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia GravisCOUR Pharma received FDA orphan drug designation for CNP-106, an investigational therapy for generalized myasthenia gravis. The biodegradable nanoparticle encapsulates seven acetylcholine receptor antigens and is being evaluated in a Phase 1b/2a clinical trial. The company expects to share data readouts as enrollment advances.Northwestern's McCormick School of EngineeringTaking the Science to Market: Start-ups at FeinbergFeinberg faculty members Dimitri Krainc, Stephen Miller, and Ruchi Gupta describe their start-ups Vanqua Bio, Cour Pharmaceuticals, and Yobee Care, respectively. Krainc's 2011 Cell paper on GBA1 mutations led to Vanqua Bio's drug development, while Miller's inverse vaccine trial is in phase 2, and Gupta's scalp products launched in 2023.